Modafinil, a novel stimulant, is selectively used in
stroke patients but without proven safety or efficacy. Current
data do not permit discrimination among these agents, identification
of optimal dosing, or selection of the preferred time of
initiation of pharmacotherapy after stroke or the duration of
treatment